{"id":"NCT02451358","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Study of a Single Dose or Two Doses of a Quadrivalent Influenza Vaccine in Subjects Aged 6 Months or Older in India","officialTitle":"Immunogenicity and Safety of a Single Dose or Two Doses Given 28 Days Apart of a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route in Subjects Aged 6 Months or Older in India","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-07-27","primaryCompletion":"2017-01-28","completion":"2017-01-28","firstPosted":"2015-05-22","resultsPosted":"2018-03-01","lastUpdate":"2022-04-19"},"enrollment":400,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Influenza"],"interventions":[{"type":"BIOLOGICAL","name":"Quadrivalent Inactivated Influenza Vaccine (2016-2017 NH formulation), No Preservative","otherNames":["QIV, No Preservative"]},{"type":"BIOLOGICAL","name":"Quadrivalent Inactivated Influenza Vaccine (2016 SH formulation), No Preservative","otherNames":["QIV, No Preservative"]},{"type":"BIOLOGICAL","name":"Quadrivalent Inactivated Influenza Vaccine (2015-2016 NH formulation), No Preservative","otherNames":["QIV, No Preservative"]},{"type":"BIOLOGICAL","name":"Quadrivalent Inactivated Influenza Vaccine (2015 SH formulation), No Preservative","otherNames":["QIV, No Preservative"]}],"arms":[{"label":"Quadrivalent Influenza Vaccine Group 1: 6 to 35 Months","type":"EXPERIMENTAL"},{"label":"Quadrivalent Influenza Vaccine Group 2: 3 to 8 Years","type":"EXPERIMENTAL"},{"label":"Quadrivalent Influenza Vaccine Group 3: 9 to 17 Years","type":"EXPERIMENTAL"},{"label":"Quadrivalent Influenza Vaccine Group 4: >=18 Years","type":"EXPERIMENTAL"}],"summary":"The aim of the study was to generate immunogenicity and safety data in the whole population to support registration of the Quadrivalent Influenza Vaccine (QIV) in India:\n\nPrimary objective:\n\n* To describe in each age group the immune response induced by a single injection (participants aged \\>9 years) or 2 injections (participants aged 6 months to 8 years) of QIV.\n\nSecondary objective:\n\n* To describe in each age group the safety profile of QIV.","primaryOutcome":{"measure":"Geometric Mean Titers (GMTs) of Influenza Vaccine Antibodies","timeFrame":"Day 0 (pre-vaccination) and 28 days post-final vaccination (post-vaccination)","effectByArm":[{"arm":"Quadrivalent Influenza Vaccine Group 1: 6 to 35 Months","deltaMin":14.4,"sd":null},{"arm":"Quadrivalent Influenza Vaccine Group 2: 3 to 8 Years","deltaMin":84.1,"sd":null},{"arm":"Quadrivalent Influenza Vaccine Group 3: 9 to 17 Years","deltaMin":107,"sd":null},{"arm":"Quadrivalent Influenza Vaccine Group 4: >=18 Years","deltaMin":44.3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":16},"locations":{"siteCount":8,"countries":["India"]},"refs":{"pmids":[],"seeAlso":["http://www.sanofipasteur.com"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":100},"commonTop":["Injection site pain","Myalgia","Pyrexia","Malaise","Headache"]}}